An interventional study of pain education and mindfulness of pain introduction and intervention in Endometriosis, Pain and Mindfulness, sponsored by Milton S. Hershey Medical Center. Active, not recruiting at 1 site in United States. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-22.
Sponsored by Milton S. Hershey Medical Center · Not applicable, Interventional, and Health services research
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 169 studies in Endometriosis with a site in United States — 38 open to participants now, 48 under way, 5 of them phase 3. Endometriosis · United States.
Among the 169 studies in Endometriosis with a site in United States, this one is the 96th largest by planned enrollment of the 131 interventional ones that give a count, is one of 11 that started in 2024, is one of 39 with no phase, reaches primary completion later than 11 of the 47 other live ones, and was the 132nd registered.
921 studies on the registry are indexed under Endometriosis; 267 are open to participants now.
Browse Endometriosis studies →38 of the 169 studies in Endometriosis with a site in United States are open now. Recruiting first, the newest first:
SWIMS America Corp. · Sites in United States
Ages 18+ · Women only
LOAM Science · Sites in United States
Ages 18–45 · Women only · Healthy volunteers
Milton S. Hershey Medical Center · Sites in United States
Ages 18–45
Staci Gruber, Ph.D. · Sites in United States
Ages 21+ · Women only
Samphire Group, Inc. · Sites in United States
Ages 18–65 · Women only · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 178 Endometriosis studies recruiting now, 52 (29%) set no upper age limit and 124 (70%) stop at 75 or younger; 18 take children under 18; 39 take healthy volunteers.
This study: 18 Years and older · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
169 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 17 · Phase 2 45 · Phase 3 22 · Phase 4 14
First in 1998; this study’s year is marked. 11 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 20 is below the median of 67 across 541 interventional studies indexed under Endometriosis.
Median enrollment 60 across the 131 interventional studies, 187 across the 38 observational. Of the 102 that completed or were terminated, 50 (49%) have results posted.
This tab as a report to print or save as PDF → With an account.
58 of 169 have an industry lead sponsor. The 10 most frequent:
Milton S. Hershey Medical Center is the lead sponsor of 492 studies on the registry; 60 are open to participants now.
Of its 58 completed or terminated interventional studies of FDA-regulated products, 46 (79%) have results posted.
Milton S. Hershey Medical Center has 8 studies filed under Endometriosis — fewer than ten, so there is no comparison to draw.
21 of the studies in Endometriosis with a site in United States that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06375811Phase 3Yale UniversityPre-IVF Treatment With a GnRH Antagonist in Women With endometriosis_temp | 2027-03-31 |
| NCT04333576Phase 3AbbVieStudy Of Oral Elagolix Tablets In Combination With Combined Oral Contraceptive Capsules/Tablets To Assess Dysmenorrhea Response In Adult Female Participants With Endometriosis And Associated Moderate To Severe Pain | 2027-07 |
| NCT05245695Aspira Women's HealthDeep Neural Network Stratification for Use Detecting Endometriosis in Women Affected by Chronic Pelvic Pain (EndoCheck) | 2026-11-30 |
| NCT06477406Mclean HospitalEvaluating the Impact of a Novel Cannabinoid Product for Endometriosis | 2026-12 |
| NCT05059626Penn State UniversityEndometriosis and Microvascular Dysfunction; Simvastatin and Duavee | 2026-12-31 |
Add all 21 to your calendar (.ics) → With an account.
Among the 169 studies in Endometriosis with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Endometriosis is a common cause of pelvic pain in women which has been historically under-studied and under-diagnosed. The goal of this research is to pilot-test the feasibility and acceptability of a manualized, single-session brief mindfulness-based intervention (BMBI) among participants with endometriosis-related chronic pelvic pain (ECPP) who undergo surgical treatment, and gather preliminary data necessary for future studies assessing BMBI's impact on outcomes in surgically-treated ECPP. This pilot study will enroll 10-20 adult participants with ECPP to receive either a BMBI adjunctive to treatment as usual (TAU; n=5-10) or education with TAU (n=5-10) prior to their ECPP surgery. The central hypothesis is the BMBI is feasible to deliver pre-operatively, acceptable to patients, and may help improve acute post-surgical outcomes through more adaptive stress coping and pain processing, enabled by mindfulness training.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Behavioral: pain education
Behavioral: mindfulness of pain introduction and intervention
Pain education
Brief mindfulness of pain introduction and intervention
Use of opioid medication
Morphine milligram equivalent following surgery
Time frame: 1 week
Use of opioid medication
Morphine milligram equivalent following surgery
Time frame: 3 months
Pain intensity
Numerical Pain Rating Scale 0-10, 10 being highest
Time frame: 1 week
Pain intensity
Numerical Pain Rating Scale 0-10, 10 being highest
Time frame: 3 months
Sleep quality (sleep duration, awakenings, efficiency)
actigraphy monitoring
Time frame: 1 week prior to surgery
Sleep quality (sleep duration, awakenings, efficiency)
actigraphy monitoring
Time frame: 1 week following surgery
Sleep report
sleep diary (hours slept, activities during day and night)
Time frame: 1 week following surgery
Sleep report
sleep diary (hours slept, activities during day and night)
Time frame: 1 week prior to surgery
Emotional functioning
Hospital Anxiety and Depression Scale 0-21, 21 is worst
Time frame: baseline
Emotional functioning
Hospital Anxiety and Depression Scale 0-21, 21 is worst
Time frame: 1 week
Emotional functioning
Hospital Anxiety and Depression Scale 0-21, 21 is worst
Time frame: 3 months
Patient global impression of change
Global Impression of change 1-7, 1 is best
Time frame: 3 months
Patient global impression of change
Global Impression of change 1-7, 1 is best
Time frame: 1 week
Pain catastrophizing
Pain catastrophizing Scale 0-52, 52 is worst
Time frame: baseline
Pain catastrophizing
Pain catastrophizing Scale 0-52, 52 is worst
Time frame: 1 week
Pain catastrophizing
Pain catastrophizing Scale 0-52, 52 is worst
Time frame: 3 months
Treatment satisfaction
Treatment satisfaction 0-10, 10 being best
Time frame: 1 week
Treatment satisfaction
Treatment satisfaction 0-10, 10 being best
Time frame: 3 months
Heart rate variability
brief HRV assessment baseline and during intervention
Time frame: baseline
Pain threshold
Pain threshold
Time frame: baseline
Temporal summation
Temporal summation of pain
Time frame: baseline
Plan to share: No
No publications or documents are linked to this record.
Started May 2024 (actual). Primary completion is estimated for Jan 2027, 32 months after the start.
Of 198 non-industry interventional studies with no phase under Endometriosis, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 44. This study's planned 32 months is above that.
Counting every sponsor, half of 213 studies reached it within 25 months; a quarter within 13 and three quarters within 44.
Primary completion moved twice since we started tracking on Sep 25, 2026: Jun 2026 → Jan 2027, last on Oct 22, 2026.
Completion moved twice since we started tracking on Sep 25, 2026: Sep 2026 → Jan 2027, last on Oct 22, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Milton S. Hershey Medical Center →